Desmoteplase
Protein / enzyme biologic targets PLG via activation
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01104467 | Aug 2010 → Aug 2013 | ischemic stroke | Lundbeck Japan K. K. | Completed | No outcome recorded |
| Phase 33 trials · 3 missed | ||||||
| Phase 3 | NCT00856661 | Apr 2009 → Oct 2014 | ischemic stroke | H. Lundbeck A/S | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT00790920 | Dec 2008 → Jul 2014 | ischemic stroke | H. Lundbeck A/S | Completed | Missed primary |
| Phase 3 | NCT00111852 | Apr 2005 → Mar 2007 | ischemic stroke | Forest Laboratories | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT00638248 Comparator | Mar 2003 → Oct 2004 | stroke disorder | PAION Deutschland GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00638781 Comparator | Mar 2001 → Oct 2003 | stroke disorder | PAION Deutschland GmbH | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Desmoteplase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00111852 ↗ |
| Known as | Desmoteplasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109084 ↗ |
| Known as | DSPA | “Desmoteplase (DSPA) with its high fibrin specificity, lack of neurotoxicity, potential neuroprotective effect, non-activation by ß-amyloid, and long terminal half-life may...” NCT00638781 ↗1“Desmoteplase (DSPA) with its high fibrin specificity, lack of neurotoxicity, potential neuroprotective effect, non-activation by ß-amyloid, and long terminal half-life may...” NCT00638248 ↗ |
| Known as | Dspa desmoteplase | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109084 ↗ |
| Known as | rDSPAalpha-1 | “The thrombolytic agent desmoteplase (recombinant Desmodus Salivary Plasminogen Activator alpha-1; rDSPAalpha-1) produced by recombinant biotechnology has its naturally...” NCT00790920 ↗1“The thrombolytic agent desmoteplase (recombinant Desmodus Salivary Plasminogen Activator alpha-1; rDSPAalpha-1) produced by recombinant biotechnology has its naturally...” NCT00856661 ↗ |
| Known as | recombinant Desmodus Salivary Plasminogen Activator alpha-1 | “The thrombolytic agent desmoteplase (recombinant Desmodus Salivary Plasminogen Activator alpha-1; rDSPAalpha-1) produced by recombinant biotechnology has its naturally...” NCT00790920 ↗1“The thrombolytic agent desmoteplase (recombinant Desmodus Salivary Plasminogen Activator alpha-1; rDSPAalpha-1) produced by recombinant biotechnology has its naturally...” NCT00856661 ↗ |
| Action | Activate | “Desmoteplase is a novel plasminogen activator with favorable features in vitro compared with available agents.” PMID 16574922 ↗ Mar 20061“Plasminogen activator” CHEMBL2109084 ↗ |
| Modality | Protein / enzyme biologic | “desmoteplase (which is a manufactured protein derived from the saliva of the vampire bat)” NCT00111852 ↗ |
| Route | Intravenous | “Desmoteplase 90 mcg/kg, intravenous administration.” NCT00111852 ↗ |
| Target | PLG | “Plasminogen activator” CHEMBL2109084 ↗ |